Riferimento:
Eur J Radiol. 2011 Nov;80(2):e116-9.
Autori:
Ambrosini V1, Campana D, Tomassetti P, Grassetto G, Rubello D, Fanti S.
Fonte:
Eur J Radiol. 2011 Nov;80(2):e116-9.
Anno:
2011
Azione:
Diagnosi di tumori neuroendocrini (NET) con 68Ga-DOTA-peptidi radiomarcati.
Target:
68Ga-DOTA/tumori neuroendocrini.
ABSTRACT
In the present review article we presented the major technical innovations regarding the diagnosis of NET with PET/CT 68Ga-DOTA-peptides compounds over conventional radiologic and scintigraphic imaging, discussing both the different types of radiopharmaceuticals commercially available, trying to making a comparison on the possible advantages and drawbacks of these radiopharmaceuticals, and providing also some technical recommendations to the radiologists and nuclear physicians for using these new methodology in an appropriate manner in the clinical setting.
Sostanze:
